Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?

@article{Ulas2015AreNR,
  title={Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?},
  author={Arife Ulas and Nilufer Avci and Tugba Fahriye Kos and Erdem Çubukçu and Omer Fatih Olmez and Nilufer Bulut and Mustafa Değirmenci},
  journal={Journal of B.U.ON. : official journal of the Balkan Union of Oncology},
  year={2015},
  volume={20 3},
  pages={714-22}
}
PURPOSE To investigate whether the pretreatment neutrophil lymphocyte ratio (NLR) and the platelet lymphocyte ratio (PLR) have any prognostic significance in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab. METHODS 187 patients were retrospectively analyzed. The patients were separated into two groups according to the mean value of NLR and PLR (low NLR≤2.38, high NLR>2.38; and low PLR≤161.28, high PLR>161.28, respectively). The relationship between pretreatment… CONTINUE READING
Highly Cited
This paper has 19 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 56 references

HERA TRIAL : 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER 2 - positive early breast cancer at 8 years of median follow up

  • A Goldhirsch, MJ Piccart-Gebhart, M Procter
  • Cancer Res
  • 2013

Similar Papers

Loading similar papers…